Molecular Biology Enzymes and Kits & Reagents Market worth $29.7 Billion by 2026 - Exclusive Report by MarketsandMarkets
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164131709
The Growth in the molecular biology enzymes and kits & reagents market is driven by factors such as increased research activities and R&D investments in the life science industry, rising number of genome projects, technological advancements in the life science industry, and rising incidence of genetic disorders.
The kits & reagents segment accounted for the largest share of the product segment in the molecular biology enzymes and kits & reagents market in 2020.
Based on products, the molecular biology enzymes and kits & reagents market is segmented into enzymes and kits & reagents. The kits & reagents segment accounted for the largest share of 85.9% of the global molecular biology enzymes and kits & reagents market in 2020. The large share of this segment can primarily be
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
Tiziana Life Sciences is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19) Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37.
Chief Scientific Officer Justin Grant said the formulations will be used in observational studies that will give way to rigorous randomized clinical trials